By Michael Dabaie

 

Roche Group's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Venclexta in combination with Gazyva for the treatment of people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Venclexta is being developed by AbbVie Inc. (ABBV) and Genentech.

The approval is based on the results of the randomized Phase III CLL14 study. Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced the risk of disease progression or death by 67% compared to a current standard of care, Genentech said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

May 15, 2019 15:15 ET (19:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Roche (QX) Charts.